MRONJ is characterized by nonhealing exposed bone in patients with a history or ongoing use of bisphosphonates (particularly with high-dose IV administration), an antiresorptive agent (eg, denosumab), or an antiangiogenic agent and no history of radiation exposure to the head and neck region.